|
1
|
Valery PC, Laversanne M and Bray F: Bone
cancer incidence by morphological subtype: A global assessment.
Cancer Causes Control. 26:1127–1139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Broadhead ML, Clark JC, Myers DE, Dass CR
and Choong PF: The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: Where do we go from here? Paediatric Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Developmental Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang J, Liu C, Qiao A, Cui Y, Zhang H,
Cui A, Zhang S, Yang Y, Xiao X, Chen Y, et al: MicroRNA-29a-c
decrease fasting blood glucose levels by negatively regulating
hepatic gluconeogenesis. J Hepatol. 58:535–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen L, Wang Q, Wang GD, Wang HS, Huang Y,
Liu XM and Cai XH: miR-16 inhibits cell proliferation by targeting
IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS
Lett. 587:1366–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y,
Wang Z, Wang Z, Cheng P, Tong D, et al: MicroRNA-133a,
downregulated in osteosarcoma, suppresses proliferation and
promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone. 56:220–226.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim HR, Shin CH, Lee H, Choi KH, Nam DH,
Ohn T and Kim HH: MicroRNA-1908-5p contributes to the oncogenic
function of the splicing factor SRSF3. Oncotarget. 8:8342–8355.
2017.PubMed/NCBI
|
|
12
|
Reinhart BJ, Slack FJ, Basson M,
Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pasquinelli AE, Reinhart BJ, Slack F,
Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B,
Müller P, et al: Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature.
408:86–89. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lan FF, Wang H, Chen YC, Chan C, Ng SS, Li
K, Xie D, He ML, Lin MC and Kung HF: Hsa-let-7g inhibits
proliferation of hepatocellular carcinoma cells by downregulation
of c-Myc and upregulation of p16(INK4A). Int J Cancer. 128:319–331.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao C, Sun G, Li S, Lang MF, Yang S, Li W
and Shi Y: MicroRNA let-7b regulates neural stem cell proliferation
and differentiation by targeting nuclear receptor TLX signaling.
Proc Nati Acad Sci USA. 107:1876–1881. 2010. View Article : Google Scholar
|
|
16
|
Fukuma H, Beppu Y, Yokoyama R and Omiya K:
TNM classification of bone and soft tissue sarcomas. Gan to kagaku
Ryoho (Japanese). 24:1035–1040. 1997.
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leichter AL, Sullivan MJ, Eccles MR and
Chatterjee A: MicroRNA expression patterns and signalling pathways
in the development and progression of childhood solid tumours. Mol
Cancer. 16:152017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang N, Song WX, Luo J, Haydon RC and He
TC: Osteosarcoma development and stem cell differentiation. Clin
Orthop Relat Res. 466:2114–2130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li S, Ferber A, Miura M and Baserga R:
Mitogenicity and transforming activity of the insulin-like growth
factor-I receptor with mutations in the tyrosine kinase domain. J
Biol Chem. 269:32558–32564. 1994.PubMed/NCBI
|
|
21
|
Kirschner LS: Inhibition of IGF-1R in
adrenocortical carcinoma. Lancet Oncol. 16:356–357. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maniscalco L, Iussich S, Morello E,
Martano M, Gattino F, Miretti S, Biolatti B, Accornero P,
Martignani E, Sánchez-Céspedes R, et al: Increased expression of
insulin-like growth factor-1 receptor is correlated with worse
survival in canine appendicular osteosarcoma. Vet J. 205:272–280.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao Y, Roth M, Piperdi S, Montoya K,
Sowers R, Rao P, Geller D, Houghton P, Kolb EA, Gill J and Gorlick
R: Insulin-like growth factor 1 receptor and response to anti-IGF1R
antibody therapy in osteosarcoma. PLoS One. 9:e1062492014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han K, Zhao T, Chen X, Bian N, Yang T, Ma
Q, Cai C, Fan Q, Zhou Y and Ma B: MicroRNA-194 suppresses
osteosarcoma cell proliferation and metastasis in vitro and in vivo
by targeting CDH2 and IGF1R. Int J Oncol. 45:1437–1449. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen G, Fang T, Huang Z, Qi Y, Du S, Di T,
Lei Z, Zhang X and Yan W: MicroRNA-133a inhibits osteosarcoma cells
proliferation and invasion via targeting IGF-1R. Cell Physiol
Biochem. 38:598–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
